About Bacterial Vaginosis Drugs BV is a vaginal disease caused due to complex alteration of flora present in the vagina. Antibacterial drugs are used for the treatment of BV, some of the most common drugs used for the treatment of the disease include Metronidazole, Clindamycin, and Tinidazole. The drugs are used in both oral and topical forms. Two types of bacteria are found in the genital parts of the women, termed as good bacteria and bad bacteria. The good bacteria present in the vagina are lactobacilli, which prevents the growth of bad bacteria. Technavio’s analysts forecast the global bacterial vaginosis drugs market to grow at a CAGR of 2.16% during the period 2017-2021. Covered in this report The report covers the present scenario and the growth prospects of the global bacterial vaginosis drugs market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The market is divided into the following segments based on geography: • Americas • APAC • EMEA Technavio's report, Global... Research Beam Model: Research Beam Product ID: 2037780 3500 USD New
Global Bacterial Vaginosis Drugs Market 2017-2021
 
 

Global Bacterial Vaginosis Drugs Market 2017-2021

  • Category : Healthcare
  • Published On : September   2017
  • Pages : 71
  • Publisher : Technavio
 
 
 
About Bacterial Vaginosis Drugs

BV is a vaginal disease caused due to complex alteration of flora present in the vagina. Antibacterial drugs are used for the treatment of BV, some of the most common drugs used for the treatment of the disease include Metronidazole, Clindamycin, and Tinidazole. The drugs are used in both oral and topical forms. Two types of bacteria are found in the genital parts of the women, termed as good bacteria and bad bacteria. The good bacteria present in the vagina are lactobacilli, which prevents the growth of bad bacteria.

Technavio’s analysts forecast the global bacterial vaginosis drugs market to grow at a CAGR of 2.16% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global bacterial vaginosis drugs market for 2017-2021. The report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio's report, Global Bacterial Vaginosis Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• Bayer
• Pfizer
• Sanofi
• Starpharma Holdings

Other prominent vendors
• Allergan
• AstraZeneca
• Cardinal Health
• Mylan
• Novartis
• Sun Pharmaceutical Industries
• Symbiomix Therapeutics
• Teva Pharmaceutical Industries

Market driver
• Unmet demand in BV treatment market
• For a full, detailed list, view our report

Market challenge
• Development of resistance against antibiotics
• For a full, detailed list, view our report

Market trend
• Growing awareness about controlled use of antibiotics
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?

You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
• Market outline
PART 05: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis
PART 06: Pipeline analysis
PART 07: Market segmentation by ROA
• Oral
• Topical
PART 08: Geographical segmentation
• BV drugs market in Americas
• BV drugs market in EMEA
• BV drugs market in APAC
PART 09: Decision framework
PART 10: Drivers and challenges
• Market drivers
• Market challenges
PART 11: Market trends
• Growing awareness about controlled use of antibiotics
• Rising popularity of topical drugs and other treatment options such as probiotic drugs
PART 12: Vendor landscape
PART 13: Key vendor analysis
• Bayer
• Pfizer
• Sanofi
• Starpharma Holdings
• Other prominent vendors
PART 14: Appendix
• List of abbreviations
List of Exhibits?
Exhibit 01: Risk factors for BV
Exhibit 02: Symptoms, diagnosis, and treatment of BV
Exhibit 03: Global BV drugs market snapshot
Exhibit 04: Global BV drugs market 2016-2021 ($ millions)
Exhibit 05: Opportunity analysis of global BV drugs market
Exhibit 06: Five forces analysis
Exhibit 07: Key pipeline molecules by vendors
Exhibit 08: Global BV drugs market: Key trials
Exhibit 09: Global BV drugs market by ROA 2016
Exhibit 10: Global BV drugs market by ROA 2016 and 2021
Exhibit 11: Basis for the choice of routes
Exhibit 12: Advantages and disadvantages of oral route of drug administration
Exhibit 13: Global BV oral drugs market 2016-2021 ($ millions)
Exhibit 14: Advantages and disadvantages of topical drugs
Exhibit 15: Global BV topical drugs market 2016-2021 ($ millions)
Exhibit 16: Segmentation of global BV drugs market by geography 2016 and 2021
Exhibit 17: Global BV drugs market revenue by geography 2016-2021 ($ millions)
Exhibit 18: Market scenario in Americas
Exhibit 19: BV drugs market in Americas 2016-2021 ($ millions)
Exhibit 20: Market scenario in EMEA
Exhibit 21: BV drugs market in EMEA 2016-2021 ($ millions)
Exhibit 22: Prevalence rate of BV in Europe
Exhibit 23: Market scenario in APAC
Exhibit 24: BV drugs market in APAC 2016-2021 ($ millions)
Exhibit 25: Complications associated with BV
Exhibit 26: Pregnancy complications due to BV
Exhibit 27: Symptoms of PID
Exhibit 28: Sociocultural factors preventing females from quality health services
Exhibit 29: Women health programs
Exhibit 30: Resistance for clindamycin
Exhibit 31: Major causes of antibiotic resistance
Exhibit 32: Competitive structure analysis of global BV drugs market 2016
Exhibit 33: Bayer: Key highlights
Exhibit 34: Bayer: Strength assessment
Exhibit 35: Bayer: Strategy assessment
Exhibit 36: Bayer: Opportunity assessment
Exhibit 37: Pfizer: Key highlights
Exhibit 38: Pfizer: Strength assessment
Exhibit 39: Pfizer: Strategy assessment
Exhibit 40: Pfizer: Opportunity assessment
Exhibit 41: Key highlights
Exhibit 42: Sanofi: Strength assessment
Exhibit 43: Sanofi: Strategy assessment
Exhibit 44: Sanofi: Opportunity assessment
Exhibit 45: Starpharma: Key highlights
Exhibit 46: Starpharma: Strength assessment
Exhibit 47: Starpharma: Strategy assessment
Exhibit 48: Starpharma: Opportunity assessment

PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter

 
 
REQUEST SAMPLE    ASK FOR DISCOUNT